The Clinical Utility of Glycated Albumin as an Index of Glycaemic Control in Type 1 Diabetic Pregnancy and its ability to predict Neonatal Outcome
Not Applicable
Completed
- Conditions
- Type 1 DiabetesPregnancyMetabolic and Endocrine - DiabetesReproductive Health and Childbirth - Normal pregnancy
- Registration Number
- ACTRN12614001295639
- Lead Sponsor
- orthern Sydney Local Health District
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Female
- Target Recruitment
- 30
Inclusion Criteria
Type 1 diabetes mellitus
- 11-18 weeks of gestation
- Aged > 18 years
Exclusion Criteria
- Severe renal impairment - > stage 3 chronic kidney disease
- Severe hepatic derangement - AST > 3 times upper limit of normal and/or ALT > 3 times upper limit of normal
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The correlation of measures of glycaemic control (as assessed by glycated albumin, HbA1c, fructosamine and 1,5-anhydroglucitol values) obtained throughout pregnancy with maternal and neonatal outcomes, particularly the incidence of macrosomia. Maternal and neonatal outcomes will be assessed by reviewing medical records and routine clinical data following delivery.<br>Maternal outcomes to be assessed include:<br>- Method of delivery (e.g. induction of labour, caesarean section)<br>- Perineal lacerations<br>- Postpartum haemorrhage<br>- Complications in labour<br>Neonatal outcomes to be assessed include:<br>- Birth weight<br>- Gestational age at birth<br>- Incidence of neonatal death<br>- Shoulder dystocia<br>- Bone fracture<br>- Nerve palsy<br>- Admission to neonatal intensive care unit (NICU)<br>- Hypoglycaemia<br>- Jaundice and/or jaundice requiring phototherapy<br>- Respiratory distress<br>[Post-pregnancy/delivery date]
- Secondary Outcome Measures
Name Time Method